

DAFTAR PUSTAKA

1. Singer, M. *et al.* The third international consensus definitions for sepsis and septic shock (sepsis-3). *JAMA - J. Am. Med. Assoc.* **315**, 801–810 (2016).
2. Ince, C. *et al.* The endothelium in sepsis. *Shock* **45**, 259–270 (2016).
3. Joffre, J., Hellman, J., Ince, C. & Ait-Oufella, H. Endothelial responses in sepsis. *Am. J. Respir. Crit. Care Med.* 202(3), 361–370 (2020)
4. Saoraya, J., Wongsamita, L., Srisawat, N. & Musikatavorn, K. Plasma syndecan-1 is associated with fluid requirements and clinical outcomes in emergency department patients with sepsis. *Am. J. Emerg. Med.* **42**, 83–89 (2021).
5. Uchimido, R., Schmidt, E. P. & Shapiro, N. I. The glycocalyx : a novel diagnostic and therapeutic target in sepsis. 1–12 (2019).
6. Marechal X, Favory R, Joulin O, Montaigne D, Hassoun S, Decoster B, et al. Endothelial glycocalyx damage during endotoxemia coincides with microcirculatory dysfunction and vascular oxidative stress. *Shock*. 2008;29(5).
7. Schouten M, Wiersinga WJ, Levi M, van der Poll T. Inflammation, endothelium, and coagulation in sepsis. *J Leukoc Biol.* 2008;83(3).
8. Sari, E. K., Hayati, Y. S. & Rokhmawati, N. L. Hubungan Skor Sofa Dengan Mortalitas Pada Pasien Sakit Kritis. *Maj. Kesehat.* **8**, 149–155 (2021).
9. Sallisalmi M, Tenhunen J, Yang R, Oksala N, Pettilä V. Vascular adhesion protein-1 and syndecan-1 in septic shock. *Acta Anaesthesiol Scand.* 2012;56(3).
10. Padberg JS, Wiesinger A, di Marco GS, Reuter S, Grabner A, Kentrup D, et al. Damage of the endothelial glycocalyx in chronic kidney disease. *Atherosclerosis.* 2014;234(2).

11. de Oliveira Neves FM, Meneses GC, Sousa NEA, de Menezes RRPPB, Parahyba MC, Martins AMC, et al. Syndecan-1 in acute decompensated heart failure - Association with renal function and mortality -. *Circulation Journal*. 2015;79(7).
12. Puskarich MA, Cornelius DC, Tharp J, Nandi U, Jones AE. Plasma syndecan-1 levels identify a cohort of patients with severe sepsis at high risk for intubation after large-volume intravenous fluid resuscitation. *J Crit Care*. 2016;36.
13. Ostrowski SR, Haase N, Müller RB, Møller MH, Pott FC, Perner A, et al. Association between biomarkers of endothelial injury and hypocoagulability in patients with severe sepsis: A prospective study. *Crit Care*. 2015;19(1).
14. Wang J bo, Guan J, Shen J, Zhou L, Zhang Y jun, Si Y fang, et al. Insulin increases shedding of syndecan-1 in the serum of patients with type 2 diabetes mellitus. *Diabetes Res Clin Pract*. 2009;86(2).
15. Anand D, Ray S, Srivastava LM, Bhargava S. Evolution of serum hyaluronan and syndecan levels in prognosis of sepsis patients. *Clin Biochem*. 2016;49(10–11).
16. Johansson PI, Haase N, Perner A, Ostrowski SR. Association between sympathoadrenal activation, fibrinolysis, and endothelial damage in septic patients: A prospective study. *J Crit Care*. 2014;29(3).
17. Suzuki K, Okada H, Sumi K, Tomita H, Kobayashi R, Ishihara T, et al. Serum syndecan-1 reflects organ dysfunction in critically ill patients. *Sci Rep*. 2021;11(1).
18. Steppan J, Hofer S, Funke B, Brenner T, Henrich M, Martin E, et al. Sepsis and major abdominal surgery lead to flaking of the endothelial glycocalyx. *Journal of Surgical Research*. 2011;165(1).
19. Vincent JL, Nelson DR, Williams MD. Is worsening multiple organ failure

- the cause of death in patients with severe sepsis? In: *Critical Care Medicine*. 2011.
20. Alsous F, Khamiees M, DeGirolamo A, Amoateng-Adjepong Y, Manthous CA. Negative fluid balance predicts survival in patients with septic shock: A retrospective pilot study. *Chest*. 2000;117(6).
 21. Kim, K. H., Cho, H. J., Kim, S. C. & Lee, J. Prognostic Value of Estimated Plasma Volume Status in Patients With Sepsis. *J. Korean Med. Sci.* **37**, 1– 10 (2022).
 22. Turcato, G., Zaboli, A., Ciccariello, L. & Pfeifer, N. Estimated plasma volume status (ePVS) could be an easy-to-use clinical tool to determine the risk of sepsis or death in patients with fever. *J. Crit. Care* **58**, 106– 112 (2020).
 23. Gao, B. *et al.* Estimated plasma volume status as a simple and accessible predictor of 28-day mortality in septic shock: insights from a retrospective study of the MIMIC-IV database. *Front. Med.* **11**, 1–10 (2024).
 24. Gyawali, B., Ramakrishna, K. & Dhamoon, A. S. Sepsis: The evolution in definition, pathophysiology, and management. *SAGE Open Med.* **7**, (2019).
 25. Acheampong, A. & Vincent, J. L. A positive fluid balance is an independent prognostic factor in patients with sepsis. *Crit. Care* **19**, 1–7 (2015).
 26. Caraballo, C. & Jaimes, F. Organ dysfunction in sepsis: An ominous trajectory from infection to death. *Yale J. Biol. Med.* **92**, 629–640 (2019).
 27. Evans, T. Diagnosis and management of sepsis. *Clin. Med. J. R. Coll. Physicians London* **18**, 146–149 (2018).
 28. Evans, L. *et al.* Executive Summary: Surviving Sepsis Campaign: International Guidelines for the Management of Sepsis and Septic Shock 2021. *Crit. Care Med.* **49**, 1974–1982 (2021).
 29. Angus, D. C. & Poll, T. van der. Severe sepsis and septic shock. *N. Engl. J. Med.* 703–707 (2012) doi:10.1007/978-81-322-0535-7_88.
 30. Vincent, J. L. *et al.* The SOFA (Sepsis-related Organ Failure Assessment)

- score to describe organ dysfunction/failure. *Intensive Care Med.* **22**, 707–710 (1996).
31. Ferreira, F. L. Serial Evaluation of the SOFA Score. *October* **286**, 1754–1758 (2001).
 32. Anjana, D. A Comparative study of APACHE II and SOFA Scoring Systems in Critically ill Patients with Sepsis. **5139**, 4–6 (2017).
 33. Wang, G. *et al.* Resuscitation fluids as drugs : targeting the endothelial glycocalyx. **135**, (2022).
 34. Chen, J. *et al.* Estimated plasma volume status (ePVS) is a predictor for acute myocardial infarction in-hospital mortality: analysis based on MIMIC-III database. *BMC Cardiovasc. Disord.* **21**, 1–10 (2021).
 35. Holzmann, M. S. *et al.* Syndecan-1 as a biomarker for sepsis survival after major abdominal surgery. *Biomark. Med.* **12**, 119–127 (2018).
 36. Suzuki, K. *et al.* Serum syndecan-1 reflects organ dysfunction in critically ill patients. *Sci. Rep.* **11**, 1–9 (2021).
 37. Hatanaka, K. *et al.* Circulating Syndecan-1 as a Predictor of Persistent Thrombocytopenia and Lethal Outcome: A Population Study of Patients With Suspected Sepsis Requiring Intensive Care. *Front. Cardiovasc. Med.* **8**, 1–8 (2021).
 38. Wiguna, Y. W., Setiawan, P., Semedi, B. P. & Purwanto, B. Syndecan-1 Laktat dan Profil Lipid sebagai Faktor Risiko Keparahan dan Mortalitas Sepsis. *J. Anestesi Perioper.* **9**, 18–26 (2021).
 39. Zhou, G., Liu, J., Zhang, H., Wang, X. & Liu, D. Elevated endothelial dysfunction-related biomarker levels indicate the severity and predict sepsis incidence. *Sci. Rep.* **12**, 1–9 (2022).
 40. Xie W., Ding, Y., Bhandari. S., Li, H., Chen, H., Jin, S., Wenf, H., Hao, Y. Clinical value of Syndecan-1 levels in trauma brain injury: A Meta-Analysis. *SHOCK* vol.61 49-54 (2024)
 41. Lestar, M. I., Gunawan, F., Erwin, S. Irsan, S. Korelasi kadar Hyaluronan dan syndecan-1 dengan angka mortalitas pasien sepsis yang dirawat di ICU. *Anesthesia & Critical Care* Vol 35 2 (2017)

42. Duarte, K. *et al.* Prognostic Value of Estimated Plasma Volume in Heart Failure. *JACC Hear. Fail.* **3**, 886–893 (2015).
43. Bale, C., Kakrani, A. L., Dabadghao, V. S. & Sharma, Z. D. Sequential organ failure assessment score as prognostic marker in critically ill patients in a tertiary care intensive care unit. **3**, 155–158 (2013).
44. Kajita, Y. *et al.* A longitudinal change of syndecan-1 predicts risk of acute respiratory distress syndrome and cumulative fluid balance in patients with septic shock : a preliminary study. 1–9 (2021).
45. Osuka, A. *et al.* Glycocalyx Shedding Is Enhanced By Age And Correlates With Increased Fluid Requirement In Patients With Major Burns. **50**, 60–65 (2018).
46. Nelson, A., Berkestedt, I., Schmidtchen, A., Ljunggren, L. & Bodelsson, M. Increased Levels Of Glycosaminoglycans During Septic Shock : Relation To Mortality And The Antibacterial Actions Of Plasma Patient characteristics. **30**, 623–627 (2008).

Lampiran 1

Tabel 1. Data Karakteristik Subjek Penelitian

No	Karakteristik / data subjek	Jumlah (n)	%	Mean (\pm SD)	Median (max-min)	Keterangan
1	R.M					
2	Umur (tahun)					
3	Jenis Kelamin					
	Laki-laki					
	Perempuan					
4	Komorbid					
	1.					
	2.					
5	Sumber infeksi					
6	Lab :					
	Wbc					
	Plt					
	Hb					
	Cratinin					
	Total bilirubin					
	Elektrolit					
7	AGD					
8	Kultur					
9	Terapi					
10	Out Come Lama rawat icu					
11	Nilai SDC-1 24 jam 72 jam					
12	Nilai ePVS 24 jam 72 jam					

Keterangan : Variabel kategorik dinyatakan dalam N (%)

Variabel kontinu dinyatakan dalam nilai rata-rata (standar deviasi) dan median (rentang maksimum-minimum)

Tabel 2. Korelasi Perubahan Kadar Serum SDC-1 dengan Skore SOFA

Variabel	Mean (± SD)	r	r²	P^{value}	ket
d SDC-1					
SOFA					

Keterangan: Analisis korelasi menggunakan uji Pearson Product Moment atau uji Spearman.

Tabel 3. Korelasi Nilai ePVS dengan Skore SOFA

Variabel	Mean (± SD)	r	r²	P^{value}	ket
ePVS					
SOFA					

Keterangan: Analisis korelasi menggunakan uji Pearson Product Moment atau uji Spearman.

Lampiran 2



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.



Contact Person: dr. Agussalim Bukhari, MMed, PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK

Nomor : 1007/UN4.6.4.5.31/ PP36/ 2024

Tanggal: 20 Nopember 2024

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH24100878		No Sponsor	
Peneliti Utama	dr. Lukman H. Semarang, Sp.An-TI		Sponsor	
Judul Peneliti	Hubungan Nilai Estimasi Plasma Volume dan Syndecan-1 terhadap sequential Organ Failure assesment Sore (SOFA) Pasien Sepsis di ICU			
No Versi Protokol	2	Tanggal Versi	19 Nopember 2024	
No Versi PSP	2	Tanggal Versi	19 Nopember 2024	
Tempat Penelitian	RSUP Dr.Wahidin Sudirohusodo Makassar			
Jenis Review	<input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku	20 Nopember 2024 sampai 20 Nopember 2025	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Prof. dr. Muh Nasrum Massi, PhD, SpMK, Subsp. Bakt(K)		Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	dr. Firdaus Hamid, PhD, SpMK(K)		Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

Lampiran 3

	ADMINISTRASI	FORMULIR 2
	Nomor : 175/05/FR2/2025	Tanggal : 15 Mei 2025
SURAT KETERANGAN SELESAI PENGAMBILAN DATA/ ANALISA BAHAN HAYATI		

Dengan hormat,

Dengan ini menerangkan bahwa peneliti/mahasiswa berikut ini :

Nama : Lukman Husein Semarang
NIM : C0182120005
Institusi : Departemen Ilmu Anestesi, Perawatan Intensif, dan Manajemen Nyeri
Sp-2 Fakultas Kedokteran UNHAS
Judul Penelitian : **Hubungan Nilai Estimasi Plasma Volume Dan Nilai Syndecan-1 Terhadap Skore SOFA Pada Pasien Sepsis Dan Syol Sepsis Di ICU.**

Telah selesai melakukan pengambilan data/ analisa bahan hayati :

Pada tanggal : 17 Maret 2025
Jumlah subjek : ± 84 sampel
Jenis data : Data Primer

Dengan staf pendamping/pembimbing :

Nama : Handayani Halik, S.Si., M.Kes.
Konsultan : -

Surat keterangan ini juga merupakan penjelasan bahwa peneliti/mahasiswa diatas tidak mempunyai sangkutan lagi pada unit/laboratorium kami.

Demikian surat ini dibuat untuk dipergunakan sebagaimana mestinya.

Pendamping/Pembimbing


Handayani Halik, S.Si., M.Kes.
NIP

Mengetahui,
Kepala Laboratorium,

dr. Rusdina Bte Ladju, Ph.D
NIP 198108302012122002



Lampiran 4

Group	Type	Sample	Original [Abs]	Fitted conc. (ng/ml)
Assay	Unknown	A1	2,4332	65.2
Assay	Unknown	A2	2,4041	64.1
Assay	Unknown	A3	2,4478	65.8
Assay	Unknown	A4	3,0678	92.3
Assay	Unknown	A5	2,4183	64.7
Assay	Unknown	A6	1,7785	41.6
Assay	Unknown	A7	2,4194	64.7
Assay	Unknown	A8	1,7442	40.5
Assay	Unknown	A9	1,7388	40.4
Assay	Unknown	A10	1,7502	40.7
Assay	Unknown	A11	2,4856	67.4
Assay	Unknown	A12	2,4669	66.6
Assay	Unknown	A13	1,7736	41.5
Assay	Unknown	A14	1,8312	43.4
Assay	Unknown	A15	1,8111	42.7
Assay	Unknown	A16	1,7837	64.3
Assay	Unknown	A17	2,4346	65.3
Assay	Unknown	A18	2,3932	41.9
Assay	Unknown	A19	2,3933	63.7
Assay	Unknown	A20	3,0686	63.7
Assay	Unknown	A21	3,0999	92.4
Assay	Unknown	A22	1,7698	93.8
Assay	Unknown	A23	1,7232	41.3
Assay	Unknown	A24	1,7506	39.8
Assay	Unknown	A25	1,8699	40.7
Assay	Unknown	A26	1,7713	44.7
Assay	Unknown	A27	1,7833	41.4
Assay	Unknown	A28	2,3968	41.8
Assay	Unknown	A29	2,6297	63.8
Assay	Unknown	A30	2,6297	73.2
Assay	Unknown	B1	1,7965	42.2
Assay	Unknown	B2	1,7366	40.2
Assay	Unknown	B3	1,7769	41.5
Assay	Unknown	B4	2,3849	63.3
Assay	Unknown	B5	1,7549	40.8
Assay	Unknown	B6	1,7329	40.1
Assay	Unknown	B7	1,7343	40.1
Assay	Unknown	B8	2,3980	63.8
Assay	Unknown	B9	1,7904	40.4
Assay	Unknown	B10	1,7953	42.0
Assay	Unknown	B11	1,7911	42.1
Assay	Unknown	B12	1,7804	42.0

Assay	Unknown	B13	1,8120	41.7
Assay	Unknown	B14	2,4037	42.7
Assay	Unknown	B15	1,9612	64.1
Assay	Unknown	B16	1,7876	47.8
Assay	Unknown	B17	2,3806	65.3
Assay	Unknown	B18	2,3753	41.9
Assay	Unknown	B19	2,3975	63.2
Assay	Unknown	B20	2,4187	63.0
Assay	Unknown	B21	1,7988	63.8
Assay	Unknown	B22	1,7159	64.7
Assay	Unknown	B23	1,7346	42.3
Assay	Unknown	B24	1,8553	39.6
Assay	Unknown	B25	1,7557	40.2
Assay	Unknown	B26	1,9442	44.1
Assay	Unknown	B27	1,9912	40.8
Assay	Unknown	B28	1,7557	47.2
Assay	Unknown	B29	1,9442	63,8
Assay	Unknown	B230	1,9912	48.8

Lampiran 5

Descriptives

		Statistic	Std. Error	
SDC1	Mean	57.1133	3.07564	
	95% Confidence Interval for Mean	Lower Bound	50.8229	
		Upper Bound	63.4037	
	5% Trimmed Mean	56.0519		
	Median	63.7000		
	Variance	283.787		
	Std. Deviation	16.84597		
	Minimum	39.80		
	Maximum	93.80		
	Range	54.00		
	Interquartile Range	23.95		
	Skewness	.726	.427	
	Kurtosis	-.254	.833	
	SDC3	Mean	67.9233	19.74067
95% Confidence Interval for Mean		Lower Bound	27.5491	
		Upper Bound	108.2975	
5% Trimmed Mean		48.4222		
Median		42.2500		
Variance		11690.822		
Std. Deviation		108.12410		
Minimum		39.60		
Maximum		638.00		
Range		598.40		
Interquartile Range		22.43		
Skewness		5.404	.427	
Kurtosis		29.445	.833	
EPV1		Mean	6.7990	.17044
	95% Confidence Interval for Mean	Lower Bound	6.4504	
		Upper Bound	7.1476	
	5% Trimmed Mean	6.7963		
	Median	7.1000		
	Variance	.872		
	Std. Deviation	.93356		

	Minimum		4.90	
	Maximum		9.00	
	Range		4.10	
	Interquartile Range		1.35	
	Skewness		-.179	.427
	Kurtosis		-.030	.833
EPV3	Mean		5.6967	.18645
	95% Confidence Interval for	Lower Bound	5.3153	
	Mean	Upper Bound	6.0780	
	5% Trimmed Mean		5.7222	
	Median		5.7500	
	Variance		1.043	
	Std. Deviation		1.02122	
	Minimum		2.90	
	Maximum		7.60	
	Range		4.70	
	Interquartile Range		1.45	
	Skewness		-.371	.427
	Kurtosis		.601	.833
SOFA1	Mean		6.3667	.47581
	95% Confidence Interval for	Lower Bound	5.3935	
	Mean	Upper Bound	7.3398	
	5% Trimmed Mean		6.2407	
	Median		6.0000	
	Variance		6.792	
	Std. Deviation		2.60614	
	Minimum		3.00	
	Maximum		12.00	
	Range		9.00	
	Interquartile Range		4.00	
	Skewness		.845	.427
	Kurtosis		.171	.833
SOFA3	Mean		4.4000	.38834
	95% Confidence Interval for	Lower Bound	3.6058	
	Mean	Upper Bound	5.1942	
	5% Trimmed Mean		4.2778	
	Median		4.0000	
	Variance		4.524	

Std. Deviation	2.12700	
Minimum	2.00	
Maximum	9.00	
Range	7.00	
Interquartile Range	2.25	
Skewness	1.001	.427
Kurtosis	.244	.833

Correlations

			SDC1	EPV1	SOFA1
Spearman's rho	SDC1	Correlation Coefficient	1.000	.280	.869**
		Sig. (2-tailed)	.	.134	.000
		N	30	30	30
	EPV1	Correlation Coefficient	.280	1.000	.292
		Sig. (2-tailed)	.134	.	.117
		N	30	30	30
	SOFA1	Correlation Coefficient	.869**	.292	1.000
		Sig. (2-tailed)	.000	.117	.
		N	30	30	30

** . Correlation is significant at the 0.01 level (2-tailed).

Correlations

			SDC3	EPV3	SOFA3
Spearman's rho	SDC3	Correlation Coefficient	1.000	.042	.647**
		Sig. (2-tailed)	.	.825	.000
		N	30	30	30
	EPV3	Correlation Coefficient	.042	1.000	-.097
		Sig. (2-tailed)	.825	.	.610
		N	30	30	30
	SOFA3	Correlation Coefficient	.647**	-.097	1.000
		Sig. (2-tailed)	.000	.610	.
		N	30	30	30

** . Correlation is significant at the 0.01 level (2-tailed).

Test Statistics^a

	SDC3 - SDC1	EPV3 - EPV1	SOFA3 - SOFA1
Z	-2.391 ^b	-4.507 ^b	-2.997 ^b
Asymp. Sig. (2-tailed)	.017	.000	.003

a. Wilcoxon Signed Ranks Test

b. Based on positive ranks.

Correlations^a

			SDC1	EPV1	SOFA1
Spearman's rho	SDC1	Correlation Coefficient	1.000	.093	.800**
		Sig. (2-tailed)	.	.741	.000
		N	15	15	15
	EPV1	Correlation Coefficient	.093	1.000	-.102
		Sig. (2-tailed)	.741	.	.718
		N	15	15	15
	SOFA1	Correlation Coefficient	.800**	-.102	1.000
		Sig. (2-tailed)	.000	.718	.
		N	15	15	15

** . Correlation is significant at the 0.01 level (2-tailed).

a. PCT_GROUP = RENDAH

Correlations^a

			SDC1	EPV1	SOFA1
Spearman's rho	SDC1	Correlation Coefficient	1.000	.619*	.864**
		Sig. (2-tailed)	.	.014	.000
		N	15	15	15
	EPV1	Correlation Coefficient	.619*	1.000	.748**
		Sig. (2-tailed)	.014	.	.001
		N	15	15	15
	SOFA1	Correlation Coefficient	.864**	.748**	1.000
		Sig. (2-tailed)	.000	.001	.
		N	15	15	15

*. Correlation is significant at the 0.05 level (2-tailed).

** . Correlation is significant at the 0.01 level (2-tailed).

a. PCT_GROUP = TINGGI